A process that provides protective therapy for biological tissues or fluids includes applying a pulsed energy source to a target tissue or a target fluid having a chronic progressive disease or a risk of having a chronic progressive disease to therapeutically or prophylactically treat the target tissue or target fluid. The pulsed energy source has energy parameters selected so as to raise the target tissue or bodily target fluid temperature up to a predetermined temperature for a short period of time to achieve a therapeutic or prophylactic effect, while the average temperature rise of the target tissue or target fluid over a longer period of time is maintained at or below a predetermined level so as not to permanently damage the target tissue or target fluid.

A catheter for ultrasonic-driven bladder therapeutic agent delivery, including: a tube having a proximal expandable portion and a distal end, and at least one transducer sleeve accommodating at least one ultrasound transducer mounted on the tube between the proximal expandable portion and the distal end.

An implantable ultrasound conducting and drug delivering apparatus includes a drug-accommodating member and a shell-shaped ultrasound-scattering member mounted on a bottom of the drug-accommodating member. The shell-shaped ultrasound-scattering member thereon has a plurality of scattering through-holes. The drug-accommodating member has at least one linking through-hole formed on the bottom thereof to communicate the bottom of the drug-accommodating member with the shell-shaped ultrasound-scattering member. The shell-shaped ultrasound-scattering member is fitted to be disposed within a physical cavity of a patient. A drug is injected into an accommodating room of the drug-accommodating member. The drug passes through the scattering through-holes and delivers to the physical cavity. An ultrasound propagates to the scattering through-holes, and is scattered by the scattering through-holes to the tissue liquid in the physical cavity, all surfaces of an inner wall of the physical cavity and all tissues neighboring the inner wall of the physical cavity.

A method for delivering ultrasound therapy using open-loop controls comprises inserting a distal tip of a therapeutic ultrasound applicator into a patient's urethra, the distal tip including an ultrasound transducer; acquiring ultrasound images of the patient's urethra and prostate with an ultrasound imaging probe; aligning the distal tip of the therapeutic ultrasound applicator with the patient's prostate using the ultrasound images; delivering therapeutic ultrasound energy to the patient's prostate, with the ultrasound transducer, according to a treatment plan, the treatment plan including a predetermined limited angular range for the therapeutic ultrasound energy that avoids the patient's rectum and neurovascular bundles, wherein the therapeutic ultrasound is delivered without temperature feedback data.

A device for treating infection within a subject includes an ultrasound transducer for applying ultrasound to a treatment site of the subject.

Disclosed are devices, systems and methods for non-invasive neuromodulation system for treating inherited or acquired retinal, choroidal and optic nerve disorders caused by acute or chronic dysregulated reduced ocular blood flow (OBF) and/or energy failure by up regulation of trigemino-vascular system (TVS), trigeminal autonomic brain reflexes (TABRs) and pancreatic trigemino-vagal reflex (TVR) through stimulation of ophthalmic nerve (V1), more specifically but not limited to SP, and CGRP containing unmyelinated C nerve fibers. The invention, in some embodiments thereof, relates to the methods for enhancing SP and CGRP expression in neurovascular tissue of the retina and choroid. The invention, in some embodiments thereof, relates to SP/CGRP mediated pathways, including those involved in vasodilatation, augmentation of OBF, RPE proliferation, prevention of apoptosis, suppressing neuroinflammation, promoting migration and differentiation of vascular endothelial cells as well as mobilization of endogenous mesenchymal stem cells (EMSCs) from the bone marrow to the circulation to accelerate tissue repair. The site of stimulation of V1 nerve includes but not limited to; nasal vestibule nasal bridge, forehead, and upper eyelids. Additionally or alternatively, the subject's sympathetic nervous system (SNS) is down regulated by sympatholytic agents specifically antioxidants. The subject's TVS and autonomic nervous system (ANS) are modulated in a manner that is effective to treat the subject for retinal, choroidal and/or optic nerve disorders. In some embodiments, the devices are handheld, portable with nose supported, having one or more intra-nasal or extra-nasal application heads. The signal can include vibration, chemical, ultrasonic, optical, electrical, hybrid electro-optical or combination of two or more of these types of stimuli. The invention, in some embodiments thereof, relates to a method for decreasing vascular resistance, enhancing vasodilatation in ophthalmic artery and its branches by the release of Vasoactive intestinal peptide (VIP),substance P and CGRP thereof increasing OBF to the retina, choroid and optic nerve in subject's with acute or chronic dysregulated, reduced OBF. The invention, in some embodiments thereof, is also related to the methods for improving delivery of oxygen, glucose, vitamin A, humoral mediators, growth factors, stem cells and pharmacological agents to the targeted tissues of the retina, choroid and optic nerve. The invention, in some embodiments thereof, relates to the methods for improving pancreatic insulin secretion, thereof to enhance glucose uptake by PRs and other retinal cells. Additionally or alternatively, the inve

Systems and methods for treating a blood clot include a catheter to be inserted into a patient. The catheter is used to deliver low stability microbubbles toward the blood clot in the patient. A thrombolytic agent is delivered toward the blood clot, and ultrasonic energy is applied to the microbubbles to vibrate the microbubbles.

A catheter-implemented transducer device for intravascular thrombolysis, is described herein. Such a transducer device includes a catheter defining a longitudinal axis and having opposed proximal and distal ends. At least one ultrasonic transducer arrangement is disposed about the distal end. The ultrasonic transducer arrangement is oriented with acoustic waves propagating parallel or perpendicular to the longitudinal axis. Optionally, the ultrasonic transducer arrangement is configured as a multi-layer stacked structure of ultrasonic transducer elements. Optionally, the ultrasonic transducer arrangement is a laser ultrasonic transducer arrangement. Optionally, the ultrasonic transducer arrangement is configured to operate in a lateral mode.

The present invention relates to a surgical kit for use in a craniectomy procedure, the surgical kit comprising: a medical device to be implanted in a cranial bone of a patient, the medical device (10) including several transducers for emitting ultrasound waves for treatment of brain tissue, a surgical accessory (20) intended to be positioned on the cranial bone of the patient, the surgical accessory (20) including a body whose outer perimeter defines the dimensions of an opening that is to be made in the cranial bone of the patient in order to receive the medical device, characterized in that the surgical accessory (20) comprises a plurality of holes (201) formed in the body, the position of each hole (201) on the body coinciding with the position of the axis of symmetry of a respective transducer, such that the accessory is able to be positioned optimally through the joint use of a neuronavigation system.

Catheter-based devices and associated methods for immune system neuromodulation of human patients are disclosed herein. One aspect of the present technology is directed to methods of treating a human patient diagnosed with an immune system condition. The methods can include intravascularly positioning a neuromodulation catheter within a blood vessel proximate to neural fibers innervating an immune system organ of the patient. The method also includes reducing sympathetic neural activity in the patient by delivering energy to the neural fibers innervating the immune system organ via the neuromodulation catheter. Reducing sympathetic neural activity improves a measurable physiological parameter corresponding to the immune system condition of the patient.